Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease.
To investigate whether an imbalance exists in the production between angiogenic and antiangiogenic growth factors in patients with Kawasaki disease (KD), we measured the serum levels of vascular endothelial growth factor (VEGF) and endostatin (ES) in 35 patients with KD, 15 patients with acute febrile diseases (disease controls) and 15 healthy children. KD patients had significantly higher VEGF levels and lower ES levels (P < 0.01) in the acute and subacute phases than the disease control and healthy children. KD patients with coronary artery lesions (CAL, n = 10) had significantly higher VEGF levels and lower ES levels (P < 0.05) in the subacute and convalescent phases than those without CAL (n = 25). The ratios of VEGF/ES in sera of KD patients with CAL were significantly higher (P < 0.05) in the acute and convalescent phases compared to those without CAL. Furthermore, the occurrence of CAL significantly correlated with the VEGF/ES ratio above 10 x 10(-3) in the subacute phase of KD (Odds ratio 17.25, P = 0.005). The findings in the present study indicate that an imbalance exists in the production between VEGF and ES in patients with KD while also suggesting that KD patients with a high VEGF/ES ratio have a significantly greater risk of CAL involvement.
Takeshita
S
S
University of Shizuoka, Junior college, Shizuoka, Japan. takesita@bambi.t.u-shizuoka-ken.ac.jp
Kawamura
Y
Y
Takabayashi
H
H
Yoshida
N
N
Nonoyama
S
S
D000208:Acute Disease; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003327:Coronary Disease / Q000097:blood / Q000000981:diagnostic imaging; D004452:Echocardiography; D043169:Endostatins / Q000097:blood*; D005260:Female; D005334:Fever / Q000097:blood; D006801:Humans; D007223:Infant; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000097:blood* / Q000000981:diagnostic imaging; D012306:Risk; D018709:Statistics, Nonparametric; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D043169:Endostatins; D042461:Vascular Endothelial Growth Factor A
Circulation. 2000 Jun 27;101(25):2935-41
10869266
EMBO J. 1999 Aug 16;18(16):4414-23
10449407
Pediatr Res. 2001 Jan;49(1):74-80
11134495
Cancer. 2001 Apr 15;91(8):1525-9
11301401
Circulation. 2002 Feb 12;105(6):766-9
11839635
Eur J Pediatr. 2002 Feb;161(2):105-11
11954744
Cancer. 2002 Oct 15;95(8):1637-43
12365010
Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1042-7
12601027
Clin Exp Immunol. 2003 Mar;131(3):536-40
12605708
FEBS Lett. 2003 Mar 27;539(1-3):149-55
12650943
Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):576-81
12692003
Cancer. 2003 Jun 1;97(11):2767-75
12767089
Mediators Inflamm. 2003 Jun;12(3):167-71
12857600
Cancer Lett. 2004 Feb 10;204(1):87-95
14744538
Clin Sci (Lond). 2004 May;106(5):439-42
14965340
J Am Coll Cardiol. 2004 Apr 21;43(8):1383-7
15093871
Pediatrics. 1974 Sep;54(3):271-6
4153258
J Pediatr. 1975 Jun;86(6):892-8
236368
Eur J Pediatr. 1978 Aug 17;129(1):17-27
679953
J Exp Med. 1986 Dec 1;164(6):1958-72
3491174
Science. 1989 Dec 8;246(4935):1306-9
2479986
Lancet. 1989 Dec 2;2(8675):1298-302
2480498
Mol Biol Cell. 1992 Feb;3(2):211-20
1550962
Cell. 1997 Jan 24;88(2):277-85
9008168
Blood. 1998 May 15;91(10):3527-61
9572988
FASEB J. 1999 Jan;13(1):9-22
9872925
Am J Cardiol. 1999 Feb 1;83(3):337-9
10072219
J Biol Chem. 1999 Apr 23;274(17):11721-6
10206987
EMBO J. 1999 Jul 15;18(14):3964-72
10406801
J Rheumatol. 2000 Oct;27(10):2339-42
11036826